The Biomarker Core's mission is three-fold:
-- I) Obtain and bank blood and cerebrospinal fluid (CSF) and measure Aβ42, total tau (tTau) and phospho-tau (pTau) in CSF to help establish biomarker diagnosis;
-- II) Develop new biofluid biomarkers and use them to understand heterogeneity in AD/ADRD and enable clinical trials to accelerate to a cure; and
-- III) Educate and train faculty, staff, trainees, students and the public in biofluid biomarker research.
Recent technological advances provide far more sensitive, specific, quantitative and precise tools for measuring diverse molecular disease processes in cerebrospinal fluid (CSF) and blood in AD/ADRD. Catalyzing and capitalizing on such tools, the Core seeks to explore clinical expression, course, mechanism and nueropathological heterogeneity to better understand AD/ADRCs and accelerate progress towards a cure.